Last edition
News about "edaravone"
Shionogi to Acquire Global Rights to RADICAVA ORS and IV RADICAVA
Shionogi plans to acquire the global rights and assets of Tanabe Pharma's RADICAVA ORS (edaravone) and IV RADICAVA, strengthening its rare disease portfolio, establishing a dedicated commercial platform in the U.S., and adding an estimated USD 700 million in annual global sales, with the transaction expected to be immediately accretive in FY26.
Edaravone | 26/12/2025 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members